Next Science Ltd
ASX:NXS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Triocean Industrial Corporation Co Ltd
TWSE:1472
|
TW |
|
LKA Gold Inc
OTC:LKAI
|
US |
|
D
|
Daesung Microbiological Labs Co Ltd
KOSDAQ:036480
|
KR |
|
F
|
Futuristic Solutions Ltd
BSE:534063
|
IN |
|
B
|
Ben Thanh Rubber JSC
VN:BRC
|
VN |
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| AU |
|
Next Science Ltd
ASX:NXS
|
42.4m AUD |
Loading...
|
|
| JP |
|
Hoya Corp
TSE:7741
|
9.8T JPY |
Loading...
|
|
| CH |
|
Alcon AG
SIX:ALC
|
29.8B CHF |
Loading...
|
|
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
36B USD |
Loading...
|
|
| DK |
|
Coloplast A/S
CSE:COLO B
|
98B DKK |
Loading...
|
|
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
12.6B USD |
Loading...
|
|
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
954.9B JPY |
Loading...
|
|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.4B GBP |
Loading...
|
|
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.9B USD |
Loading...
|
|
| CN |
|
Intco Medical Technology Co Ltd
SZSE:300677
|
38B CNY |
Loading...
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
37.6B CNY |
Loading...
|
Market Distribution
| Min | -16 177 900% |
| 30th Percentile | -544.7% |
| Median | -27.7% |
| 70th Percentile | 3.1% |
| Max | 3 174 540% |
Other Profitability Ratios
Next Science Ltd
Glance View
Next Science Ltd. engages in the research, development, and distribution of technologies with bacterial issue application. The company is headquartered in Chatswood, New South Wales. The company went IPO on 2019-04-18. The firm's principal activities include development and commercialization of XBIO technology. The XBIO technology is a non-toxic technology used in solving the problems of bacterial biofilms. The firm's product includes XPERIENCE, SURGX, BACTISURE and BLASTX. The XPERIENCE product is an antimicrobial solution used to prevent surgical site infections by rinsing away debris and microorganisms. SURGX Sterile Antimicrobial Gel is used to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-based bacteria within the gel. The BLASTX is an antimicrobial wound gel.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Next Science Ltd is -42.7%, which is above its 3-year median of -62%.
Over the last 3 years, Next Science Ltd’s Net Margin has increased from -112.4% to -42.7%. During this period, it reached a low of -112.4% on Jun 30, 2022 and a high of -42.7% on Jun 30, 2025.
